Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Sep;72(3):774–776. doi: 10.1038/bjc.1995.409

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.

C L Hanna 1, F E McKinna 1, L B Williams 1, D Morrey 1, M Adams 1, M D Mason 1, T S Maughan 1
PMCID: PMC2033907  PMID: 7669593

Abstract

We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer. Patients received 200 mg m-2 (maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluorouracil 600 mg m-2 over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment.

Full text

PDF
774

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Gramont A., Krulik M., Cady J., Lagadec B., Maisani J. E., Loiseau J. P., Grange J. D., Gonzalez-Canali G., Demuynck B., Louvet C. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1499–1503. doi: 10.1016/0277-5379(88)90341-0. [DOI] [PubMed] [Google Scholar]
  2. Jodrell D. I., Murray L. S., Reed N. S., Canney P. A., Kaye S. B., Cassidy J. Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer. 1994 Oct;70(4):749–752. doi: 10.1038/bjc.1994.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Johnson P. W., Thompson P. I., Seymour M. T., Deasy N. P., Thuraisingham R. C., Slevin M. L., Wrigley P. F. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer. 1991 Sep;64(3):603–605. doi: 10.1038/bjc.1991.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Poon M. A., O'Connell M. J., Wieand H. S., Krook J. E., Gerstner J. B., Tschetter L. K., Levitt R., Kardinal C. G., Mailliard J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991 Nov;9(11):1967–1972. doi: 10.1200/JCO.1991.9.11.1967. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES